Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aloka Chakravarty

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Pharmacoepidemiology and Drug Safety|January 13, 2025
Characterization of SARS-CoV-2 Diagnostic Tests and Liver Function Tests Among Patients With COVID-19 Diagnosed in Outpatient Settings Using Administrative Healthcare Data and Data From Commercial LaboratoriesAyad K Ali, Aidan Baglivo, Priya Govil, et al.
Plos One|September 26, 2022
Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemicSarah E Vititoe, Imaani J Easthausen, Tamar Lasky, et al.
Pharmacoepidemiology and Drug Safety|July 16, 2016
Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome associationSusan Gruber, Aloka Chakravarty, Susan R Heckbert, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2022
Categorization of COVID-19 severity to determine mortality riskElizabeth M Garry, Andrew R Weckstein, Kenneth Quinto, et al.
Epidemiology (Cambridge, Mass.)|September 25, 2025
Illustrating an Adaptive Prespecification Framework for Observational Research: Target Trial Emulations Comparing Immunomodulator Treatments for COVID-19Andrew R Weckstein, Vera Frajzyngier, Sarah E Vititoe, et al.
Open Forum Infectious Diseases|July 27, 2023
A Descriptive Cohort Study of Drug Utilization Patterns Among Patients Hospitalized With Coronavirus Disease 2019 in the United States, January 2021-February 2022Sarah E Vititoe, Priya Govil, Aidan Baglivo, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Pharmacoepidemiology and Drug Safety|January 13, 2025
Characterization of SARS-CoV-2 Diagnostic Tests and Liver Function Tests Among Patients With COVID-19 Diagnosed in Outpatient Settings Using Administrative Healthcare Data and Data From Commercial LaboratoriesAyad K Ali, Aidan Baglivo, Priya Govil, et al.
Plos One|September 26, 2022
Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemicSarah E Vititoe, Imaani J Easthausen, Tamar Lasky, et al.
Pharmacoepidemiology and Drug Safety|July 16, 2016
Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome associationSusan Gruber, Aloka Chakravarty, Susan R Heckbert, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2022
Categorization of COVID-19 severity to determine mortality riskElizabeth M Garry, Andrew R Weckstein, Kenneth Quinto, et al.
Epidemiology (Cambridge, Mass.)|September 25, 2025
Illustrating an Adaptive Prespecification Framework for Observational Research: Target Trial Emulations Comparing Immunomodulator Treatments for COVID-19Andrew R Weckstein, Vera Frajzyngier, Sarah E Vititoe, et al.
Open Forum Infectious Diseases|July 27, 2023
A Descriptive Cohort Study of Drug Utilization Patterns Among Patients Hospitalized With Coronavirus Disease 2019 in the United States, January 2021-February 2022Sarah E Vititoe, Priya Govil, Aidan Baglivo, et al.
Pageof 2